Ark cuts costs as it awaits Cerepro appeal decision
28 January 2010
Sukaina Virji
28 January 2010
Sukaina Virji
sukaina.virji@informa.com
Ark Therapeutics has implemented a series of cost-cutting measures in order to extend its cash runway, following the EU CHMP's recent rejection of its lead product Cerepro (sitimagene ceradenovec) for the treatment of operable high-grade glioma (
Please Login to read the full article.
RELATED CONTENT
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
